{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-197282","form_type":"8-K","ticker":"RMD","cik":"0000943819","company_name":"RESMED INC","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.957712+00:00","generated_at":"2026-05-15T01:29:34.384101+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ResMed CFO Brett Sandercock retires; Aaron Bloomer appointed successor","bullets":["Brett Sandercock retires as CFO effective May 4, 2026; remains special advisor to CEO through Dec 2027.","Aaron Bloomer appointed CFO effective May 4; previously CFO of Exact Sciences (recently acquired by Abbott).","Bloomer compensation: $725k salary, $150k sign-on bonus, $3.3M equity grant (RSUs/PSUs with TSR metrics).","Resmed reiterates FY2026 guidance: gross margin 62-63%, SG&A 19-20%, R&D 6-7%, tax rate 21-23%.","Sandercock's retirement not due to any disagreement; retains salary, benefits and equity vesting through 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-197282","json":"https://secwatch.observer/filing/0001193125-26-197282.json","markdown":"https://secwatch.observer/filing/0001193125-26-197282.md","text":"https://secwatch.observer/filing/0001193125-26-197282.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/943819/000119312526197282/0001193125-26-197282-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/943819/000119312526197282/d50610d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:29:34.384101+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ddbe6d6941","claim":"Aaron Bloomer was appointed as Chief Financial Officer at RESMED INC.","evidence_excerpt":"On April 30, 2026, the Company also announced it appointed Aaron Bloomer, age 40, as Chief Financial Officer, effective May 4, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/943819/000119312526197282/0001193125-26-197282-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}]},{"claim_id":"f69ce28f92","claim":"Brett Sandercock departed as Chief Financial Officer at RESMED INC.","evidence_excerpt":"On April 30, 2026, ResMed Inc. (the “Company”) announced that Brett Sandercock, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, will retire from his role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/943819/000119312526197282/0001193125-26-197282-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"Chief Financial Officer"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}